Artificial intelligence continues to drive transformative advances in biotech. At the BIO 2025 AI Summit, industry leaders highlighted both rapid growth and the nascent, evolving nature of AI in drug discovery, clinical trials, and genomics. Researchers from the University of Sheffield and AstraZeneca developed MapDiff, a machine learning framework that improves accuracy in inverse protein folding, facilitating novel protein design for therapeutics. Additionally, moPepGen, a new computational tool from UCLA and the University of Toronto, enhances detection of hidden protein variants tied to genetic mutations, advancing proteogenomic research with implications for personalized medicine and cancer treatment. These innovations underscore AI's growing role but also stress the importance of sustained infrastructure development and multidisciplinary expertise.